Melanoma Clinical Trial

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Summary

UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma. This study will explore the safety, tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also receiving pembrolizumab.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Stage IIIB, IIIC or IV melanoma
Previously untreated and eligible for pembrolizumab treatment (prior treatment with BRAF and MEK inhibitors permitted) 3) Adequate blood, liver and kidney function 4) Consent to undergo tumor biopsies during the study

Exclusion Criteria:

Uveal or ocular malignant melanoma
History of hematologic or primary solid tumor malignancy with the exception of patients in remission for at least 5 years, as judged by the investigator are allowed
Prior systemic treatment for unresectable or metastatic melanoma. Exception: Prior treatment with BRAF and MEK inhibitors permitted. A washout period of at least 3-half-lives (median terminal half-life) prior to the first dose of trial treatment must have elapsed.
Prior therapy with an anti-CTLA4, anti-PD-1, anti-PD-L1, anti-PD-L2 agent or oncolytic virus.
Known hypersensitivity to GM-CSF
Women who are breastfeeding, pregnant or expect to be pregnant during the study through 6 months after the last dose
Men who plan to become a father during the study through 4 months after the last dose of study medication
Known history of, or any evidence of active, non-infectious pneumonitis
History of cardiac disease

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT03538314

Recruitment Status:

Active, not recruiting

Sponsor:

Ultimovacs ASA

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

John Wayne Cancer Center
Santa Monica California, 90404, United States
University of Iowa Carver College of Medicine
Iowa City Iowa, 52242, United States
St. Luke's University Health Network
Easton Pennsylvania, 18045, United States
University of Utah Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT03538314

Recruitment Status:

Active, not recruiting

Sponsor:


Ultimovacs ASA

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.